20:07 , Jul 13, 2018 |  BC Week In Review  |  Financial News

Nohla adds $11M to series B

Off-the-shelf cell therapy company Nohla Therapeutics Inc. (Seattle, Wash.) raised an additional $11 million on June 11 in the second close of a series B financing, bringing the round’s total to $56 million. New investors...
19:58 , Jul 13, 2018 |  BC Week In Review  |  Company News

Genmab, Immatics in bispecific immunotherapy deal

Immatics Biotechnologies GmbH (Tuebingen, Germany) granted Genmab A/S (CSE:GEN; Pink:GMXAY) exclusive, worldwide rights to develop bispecific, T cell-engaging immunotherapies against three targets to treat multiple cancer indications. Immatics will receive $54 million up front and is...
21:01 , Jul 12, 2018 |  BC Extra  |  Company News

Genmab, Immatics in bispecific immunotherapy deal

Immatics Biotechnologies GmbH (Tuebingen, Germany) granted Genmab A/S (CSE:GEN; Pink:GMXAY) exclusive, worldwide rights to develop bispecific, T cell-engaging immunotherapies against three targets to treat multiple cancer indications. Immatics will receive $54 million up front and is...
16:42 , Jul 6, 2018 |  BC Week In Review  |  Company News

Athenex Announces Two China Deals Plus $100M Raise

Athenex Inc. (NASDAQ:ATNX) entered into a pair of deals with Chinese partners on a newsy July 2 that also saw the biotech raise $100 million in equity and debt. The company said it is forming a...
23:18 , Jul 2, 2018 |  BC Extra  |  Company News

Athenex announces two China deals plus $100M raise

Athenex Inc. (NASDAQ:ATNX) entered into a pair of deals with Chinese partners on a newsy Monday that also saw the biotech raise $100 million in equity and debt. The company said it is forming a JV,...
00:43 , Jun 29, 2018 |  BC Innovations  |  Product R&D

Highly personal

Pact Pharma Inc. has raised $120 million in venture financing to tackle one of the most complex forms of personalized medicine proposed to date: neoantigen-targeted T cells. Backed by Alphabet Inc.’s GV, the company is...
18:25 , Jun 22, 2018 |  BC Week In Review  |  Clinical News

Antibodies neutralize Catalyst's Factor IX variant

Catalyst Biosciences Inc. (NASDAQ:CBIO) reported that two patients developed neutralizing antibodies to its CB 2679d (ISU 304). The antibodies were observed after treatment in the sixth and latest dose cohort of a Phase I/II trial...
23:12 , Jun 18, 2018 |  BC Extra  |  Clinical News

Antibodies neutralize Catalyst's Factor IX variant, crater stock

Catalyst Biosciences Inc. (NASDAQ:CBIO) fell $16.14 (64%) to $9.11 Monday when it reported that two patients developed neutralizing antibodies to CB 2679d (ISU 304). The antibodies were observed after treatment in the sixth and latest...
19:54 , May 25, 2018 |  BioCentury  |  Emerging Company Profile

Universal ambitions

Emergex Vaccines Holdings Ltd. is making synthetic peptide vaccines it thinks could provide universal immunity -- and at a fraction of the time and cost of traditional vaccine development. Emergex launched in 2016 with IP acquired...
02:30 , May 18, 2018 |  BC Week In Review  |  Financial News

Arch leads Nohla's $45M series B

Off-the-shelf cell therapy company Nohla Therapeutics Inc. (Seattle, Wash.) raised $45 million on May 15 in a series B round led by existing investor Arch Venture Partners. Also participating were new investors Fidelity Management and...